Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on X:
“In RAS-mutant mPDAC (n=40; efficacy-evaluable n=35), 1L daraxonrasib shows:
- ORR 51%
- DCR 97%
- 6-mo PFS 71% | OS 83%
- Deep ctDNA responses (100% VAF reduction; 57% clearance; n=28)
- Manageable safety (no G4/5 TRAEs)
Encouraging early signal beyond chemotherapy.
Phase 3 (RASolute-303) ongoing.”
Other articles featuring Amol Akhade.